4//SEC Filing
Larkin Finbar 4
Accession 0001765581-23-000032
CIK 0001232524other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 9:33 PM ET
Size
12.5 KB
Accession
0001765581-23-000032
Insider Transaction Report
Form 4
Larkin Finbar
SVP, Technical Development
Transactions
- Award
Ordinary Shares
2023-03-03+4,373→ 23,854 total - Exercise/Conversion
Ordinary Shares
2023-03-06$58.72/sh+1,706$100,176→ 25,560 total - Sale
Ordinary Shares
2023-03-06$143.92/sh−1,706$245,526→ 23,854 total - Sale
Ordinary Shares
2023-03-07$140.76/sh−2,075$292,081→ 21,779 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-03-06−1,706→ 0 totalExercise: $58.72Exp: 2023-05-02→ Ordinary Shares (1,706 underlying)
Footnotes (5)
- [F1]These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
- [F2]Includes 72 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022.
- [F3]Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- [F4]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F5]These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, May 3, 2013, with 1/4th vesting on April 9, 2014 and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.
Documents
Issuer
Jazz Pharmaceuticals plc
CIK 0001232524
Entity typeother
Related Parties
1- filerCIK 0001793243
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 9:33 PM ET
- Size
- 12.5 KB